
AstraZeneca, and its biologics/R&D arm MedImmune, have won FDA Breakthrough Therapy status for their bladder cancer drug durvalumab (MEDI4736), which …

Roche has announced updated results from a pivotal Phase II study, showing its investigational cancer immunotherapy atezolizumab extended median progression …

A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …

Roche’s most advanced experimental cancer immunotherapy has had impressive results in a small Phase I trial, reducing tumour size in …

